$500 Billion in New U.S. Biopharmaceutical Investment
PhRMA member companies are investing to fuel innovation and bring new jobs to communities across America. Our new investments will deliver a $1.2 trillion boost to the U.S. economy.
Where’s the Drug Dollar Going?
Our current system is inefficient and costs Americans more than it should due to unnecessary bureaucracy. In fact, half of every dollar goes to someone who did not make the medicine.
Lilly invests in Virginia to expand U.S. manufacturing and advance next-generation medicines
Lilly’s new state-of-the-art facility in Virginia will strengthen America’s biopharmaceutical manufacturing capabilities and create economic opportunities for workers and communities across the state.
Biogen Deepens U.S. Manufacturing Footprint to Advance Cutting-Edge Therapies
Biogen’s continued investment in North Carolina has created a hub for biotech innovation and economic opportunity.
Merck Expands Its 85-Year Manufacturing Presence in Virginia
Merck’s new manufacturing facility in Elkton, Virginia builds on a long-standing investment in the region and continued commitment to deliver innovative treatments to patients.
Novartis Strengthens American Manufacturing Leadership in Radioligand Therapy
Novartis’s new radioligand therapy facilities, including the Carlsbad, California site, expand domestic manufacturing to accelerate the delivery of breakthrough cancer treatments to American patients.
A New Era of Biopharmaceutical Innovation
The biopharmaceutical industry is on the brink of unprecedented breakthroughs, with the potential to revolutionize health care, reduce the burden of disease and create a healthier future for all.
Our Work in Action
To maintain America’s global leadership, we need to support the next generation of innovation in medicine.
